Literature DB >> 33420100

Comparison of short-pulse subthreshold (532 nm) and infrared micropulse (810 nm) macular laser for diabetic macular edema.

Abdulrahman Al-Barki1, Lamia Al-Hijji1, Robin High2, Patrik Schatz1,3, Diana Do4, Quan D Nguyen4, Jeffrey K Luttrull5, Igor Kozak6,7.   

Abstract

The purpose of the study was to assess both anatomic and functional outcomes between short-pulse continuous wavelength and infrared micropulse lasers in the treatment of DME. This was a prospective interventional study from tertiary care eye hospital-King Khaled Eye Specialist Hospital (Riyadh, Saudi Arabia). Patients with center-involving diabetic macular edema were treated with subthreshold laser therapy. Patients in the micropulse group were treated with the 810-nm diode micropulse scanning laser TxCell (IRIDEX Corporation, Mountain View, CA, USA) (subthreshold micropulse-STMP group). Laser was applied according to recommendations for MicroPulse (125 microns spot size, 300 ms pulse duration and power adjustment following barely visible testing burn) in a confluent mode (low intensity/high density) to the entire area of the macular edema. Patients in the short-pulse group were treated with grid pattern laser with 20 ms pulse PASCAL laser 532 nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn (EndPoint 30% and EndPoint 50% groups, respectively). Main outcome measures included best-corrected visual acuity (BCVA in logMAR) and foveal thickness at baseline and the last follow-up visit at 6 months. There were 44 eyes in the micropulse group, 54 eyes in the EndPoint 50% group and 18 eyes in the EndPoint 30% group. BCVA for the whole cohort (logMAR) was 0.451 (Snellen equivalent 20/56) at baseline, 0.495 (Snellen equivalent 20/62) (p = 0.053) at 3 months, and 0.494 (Snellen equivalent 20/62) at the last follow-up (p = 0.052). Foveal thickness for the whole cohort was 378.2 ± 51.7 microns at baseline, 347.2 ± 61.3 microns (p = 0.002) at 3 months, and 346.0 ± 24.6 microns at the final follow-up (p = 0.027). As such the short-pulse system yields more temporary reduction in edema. Comparison of BCVA between baseline and 6 months for EndPoint 30%, EndPoint 50% and STMP groups was p = 0.88, p = 0.76 and p = 0.003, respectively. Comparison of foveal thickness between baseline and 6 months for EndPoint 30%, EndPoint 50% and STMP groups was p = 0.38, p = 0.22 and p = 0.14, respectively. We conclude that the infrared micropulse system seems to improve functional outcomes. When applied according to previously published reports, short-pulse system may yield more temporary reduction in edema while infrared micropulse system may yield slightly better functional outcomes.

Entities:  

Year:  2021        PMID: 33420100      PMCID: PMC7794500          DOI: 10.1038/s41598-020-79699-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

1.  Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema.

Authors:  Keiji Inagaki; Kishiko Ohkoshi; Sachiko Ohde; Gautam A Deshpande; Nobuyuki Ebihara; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2014-11-14       Impact factor: 2.447

2.  SUBTHRESHOLD MICROPULSE DIODE LASER VERSUS CONVENTIONAL LASER PHOTOCOAGULATION FOR DIABETIC MACULAR EDEMA: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Guohai Chen; Radouil Tzekov; Wensheng Li; Fangzheng Jiang; Sihong Mao; Yuhua Tong
Journal:  Retina       Date:  2016-11       Impact factor: 4.256

3.  Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

4.  SUBTHRESHOLD MICROPULSE YELLOW LASER VERSUS SUBTHRESHOLD MICROPULSE INFRARED LASER IN CENTER-INVOLVING DIABETIC MACULAR EDEMA: Morphologic and Functional Safety.

Authors:  Stela Vujosevic; Ferdinando Martini; Evelyn Longhin; Enrica Convento; Fabiano Cavarzeran; Edoardo Midena
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

5.  Autofluorescence imaging after selective RPE laser treatment in macular diseases and clinical outcome: a pilot study.

Authors:  C Framme; R Brinkmann; R Birngruber; J Roider
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

6.  Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.

Authors:  J Figueira; J Khan; S Nunes; S Sivaprasad; A Rosa; J F de Abreu; J G Cunha-Vaz; N V Chong
Journal:  Br J Ophthalmol       Date:  2008-12-03       Impact factor: 4.638

7.  Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema.

Authors:  David J Browning; Adam R Glassman; Lloyd P Aiello; Neil M Bressler; Susan B Bressler; Ronald P Danis; Matthew D Davis; Frederick L Ferris; Suber S Huang; Peter K Kaiser; Craig Kollman; Srinavas Sadda; Ingrid U Scott; Haijing Qin
Journal:  Ophthalmology       Date:  2008-08       Impact factor: 12.079

8.  Subthreshold micropulse diode laser treatment in diabetic macular oedema.

Authors:  M L Laursen; F Moeller; B Sander; A K Sjoelie
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

9.  Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation.

Authors:  Stela Vujosevic; Elisa Bottega; Margherita Casciano; Elisabetta Pilotto; Enrica Convento; Edoardo Midena
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

10.  Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema.

Authors:  Jay Chhablani; Rayan Alshareef; David Ta Kim; Raja Narayanan; Abhilash Goud; Annie Mathai
Journal:  BMC Ophthalmol       Date:  2018-07-11       Impact factor: 2.209

View more
  1 in total

1.  Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema.

Authors:  Tomoaki Tatsumi; Yoko Takatsuna; Toshiyuki Oshitari; Tomomi Kaiho; Yohei Kawasaki; Yuki Shiko; Takeshi Sugawara; Takayuki Baba; Shuichi Yamamoto
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.